Search Results 1321-1330 of 16300 for substance P

  1. Clinical trials - Oncology (Medical)

    ... P. prophylactic PLND Q. no prophylactic PLND. Establishment of Preclinical Models from Patients with Gynecological Malignancies. Rochester, Minn., Scottsdale ...

  2. Oncology (Medical) - Clinical trials

    [MUSIC PLAYING]. Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first.

  3. PSRP Platform Base - Product Surveillance Registry - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  4. PAC203: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL) (PACIFICA) - Mayo Clinic

    This study is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with myelofibrosis and severe thrombocytopenia ( ...

  5. Steve K. Poon, M.D. - Doctors and Medical Staff - Mayo Clinic

    MemberSubstance and Alcohol Abuse Screening and Brief Intervention and Referral to Treatment Task Force (C3-SBIRT), Arizona State University Health Services ...

  6. Publications - Kevin J. Wu, M.D. - Mayo Clinic

    Vishnu P, Colon-Otero G, Kennedy GT, Marlow LA, Kennedy WP, Wu KJ, Santoso JT, Copland JA. RhoB mediates antitumor synergy of combined ixabepilone and ...

  7. Clinical trials - Oncology (Medical)

    Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without ...

  8. Primary sclerosing cholangitis - Doctors and departments - Mayo Clinic

    Displaying 1-1 out of 1 doctors available. Last Name Initial: K. Andrew P. Keaveny, M.D.. Transplant Hepatologist. Jacksonville, FL ...

  9. Clinical trials - Oncology (Medical)

    Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without ...

  10. Publications - Fernando A. Rivera, M.D. - Mayo Clinic

    Munipalli B, Strothers S, Rivera F, Malavet P, Mitri G, Abu Dabrh AM, Dawson NL. Association of Vitamin B12, Vitamin D, and Thyroid-Stimulating Hormone With ...